Zacks.com on MSN3h
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen (BIIB) Gets a Buy from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Hosted on MSN2h
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a five-day winning streak.
PMLiVE7h
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
Earnings call transcript: BXP Inc Q4 2024 sees unexpected earnings dip
Boston Properties (NYSE:BXP) reported its fourth-quarter 2024 earnings, revealing a significant miss on earnings per share ...
marketinference8h
Sage Therapeutics Rejects Biogen's Acquisition Proposal
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...